Innovation
DETERA Therapeutics, a peptide to prevent crescentic glomerulonephritis (CGN)
… start-up DETERA Therapeutics is developing a drug candidate for crescentic glomerulonephritis (CGN). This treatment … Santoro went on to manage several biotechnology companies for more than ten years. With DETERA Therapeutics, the trio … phase. The start-up's co-founders are preparing the application for phase I trials in humans, which should be …
Published on: